WO2025172927 - PHARMACEUTICAL COMPOSITIONS FOR HERPES VIRUS
National phase entry is expected:
Publication Number
WO/2025/172927
Publication Date
21.08.2025
International Application No.
PCT/IB2025/051613
International Filing Date
14.02.2025
Title **
[English]
PHARMACEUTICAL COMPOSITIONS FOR HERPES VIRUS
[French]
COMPOSITIONS PHARMACEUTIQUES CONTRE LE VIRUS DE L'HERPÈS
Applicants **
ASSEMBLY BIOSCIENCES, INC.
GILEAD SCIENCES, INC.
Inventors
CHO, Aesop
WANG, Ting
YIN, Daniel H.
NARAYANAN, Eshwar
ZONG, Zhixin
Priority Data
63/554,400
16.02.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2542 | |
| EPO | Filing, Examination, Granting | 13309 | |
| Japan | Filing, Examination, Granting | 2420 | |
| South Korea | Filing, Examination, Granting | 2535 | |
| USA | Filing, Examination, Granting | 5340 |
Total:
26,146
Contact Us
Abstract[English]
The present invention relates to methods and compositions for treating and/or inhibiting the development or progression of diseases or disorders caused by, or associated with, herpes virus infection. In particular, provided are long-acting injectable depot pharmaceutical compositions comprising Compound 1 or a pharmaceutically acceptable salt thereof; methods for their manufacture; and the use of said pharmaceutical compositions as a medicament and for the treatment of diseases or disorders caused by, or associated with, herpes virus.[French]
La présente invention concerne des méthodes et des compositions pour le traitement et/ou l'inhibition du développement ou de la progression de maladies ou de troubles provoqués par une infection par le virus de l'herpès ou associés à celle-ci. En particulier, l'invention concerne des compositions pharmaceutiques sous forme de dépôt injectables à action prolongée comprenant le composé 1 ou un sel pharmaceutiquement acceptable de celui-ci ; des procédés pour leur fabrication ; et l'utilisation desdites compositions pharmaceutiques en tant que médicament et pour le traitement de maladies ou de troubles provoqués par, ou associés à, le virus de l'herpès.